Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist

Add time:08/08/2019    Source:sciencedirect.com

Structure–activity relationship studies in a series of diarylpyrazolyl thiadiazoles identified cannabinoid-1 receptor antagonists with excellent potency and selectivity. Based on its exceptional in vivo efficacy in animal models and its favorable pharmacokinetic and toxicological profiles, 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) was selected as a preclinical candidate for the treatment of obesity.

We also recommend Trading Suppliers and Manufacturers of 2-(1-methyl-1H-pyrazol-5-yl)phenol (cas 123532-22-9). Pls Click Website Link as below: cas 123532-22-9 suppliers

Prev:Presence of π…π and CH…π interactions in the new Schiff base 2-{(E)-[(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)imino]methyl}phenol: Experimental and DFT computational studies
Next:Structure, magnetism and reactivity of a {MnIII(μ-O)2MnIV}3+ core towards oxidation of phenols)